Employees: 1,973
Size Genky DrugStores (9267.T) is a Japan Consumer Staples company (Drugstore Chains) with a market value of $728M, the 890th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥3,715 on 18 Nov 2026.
Performance Over six months the shares gained 2.6%, against -16.8% for the median peer and -1.4% for the Japan market (cap-weighted) — 5th highest of 15 in its peer set.
Growth Revenue grew 8.4% over the last twelve months (peer median +3.9%); the operating margin is 4.8% (peer median 3.8%).
Valuation It trades at 13.9× forward earnings against a peer median of 16.1× (4th cheapest of 8).
Capital Return on invested capital runs 2.4 points above its cost of capital (6.0% WACC).
Next results Next results expected around 2 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | ¥224B | ¥221B | ¥201B | ¥185B | ¥169B |
| Revenue growth | — | +10% | +9% | +9% | — |
| Gross profit | ¥45.7B | ¥38.3B | ¥35.1B | ¥32.5B | ¥29.9B |
| EBITDA | ¥18.2B | ¥18.1B | ¥16.0B | ¥14.6B | ¥11.7B |
| Net income | ¥7.72B | ¥7.88B | ¥7.07B | ¥6.32B | ¥4.76B |
| Free cash flow | n/a | -¥3.13B | -¥2.50B | ¥2.98B | -¥1.12B |
| Capital expenditure | n/a | ¥20.1B | ¥15.1B | ¥10.4B | ¥9.93B |
| Total debt | ¥40.5B | ¥39.6B | ¥34.4B | ¥30.6B | ¥32.4B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 9267.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.8% | -5.7% | highest of 15 |
| 6-month return | +2.6% | -16.8% | 5th highest of 15 |
| Distance from 52-week high | -29.8% | -41.8% | 7th highest of 15 |
| Revenue growth (TTM) | +8.4% | +3.9% | 7th highest of 15 |
| Operating margin | 4.8% | 3.8% | 5th highest of 15 |
| Forward P/E | 13.9× | 16.1× | 4th cheapest of 8 |
| ROIC minus cost of capital | +2.4 pp | +2.0 pp | 8th highest of 15 |
| EV / EBITDA | 7.8× | 5.8× | 2nd most expensive of 5 |
| Net debt / EBITDA | 1.5× | 0.6× | 3rd most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Genky DrugStores 9267.T | Japan | $728M | +3% | +8% | 5% | 13.9× | n/a | n/a |
| Anhui Huaren Health Pharmaceutical 301408.SZ | China | $745M | -32% | +15% | 8% | n/a | -7.5% | +23.3% |
| Shu Yu Civilian Pharmacy 301017.SZ | China | $701M | -11% | +9% | 2% | n/a | 1.1% | +17.4% |
| MedPlus Health Services MEDPLUS.NS | India | $771M | -36% | +21% | 4% | 33.9× | 18.6% | +17.6% |
| Cawachi 2664.T | Japan | $562M | +31% | -1% | 2% | n/a | -6.1% | 0.0% |
| Qol 3034.T | Japan | $561M | +26% | +5% | 6% | 10.5× | -16.6% | +12.4% |
| Beijing Konruns Pharmaceutical 603590.SS | China | $558M | -33% | -1% | 17% | 19.0× | 12.4% | +2.7% |
| Luyan Pharma 002788.SZ | China | $514M | -32% | +3% | 3% | n/a | -0.4% | +6.5% |
| Yixintang Pharmaceutical 002727.SZ | China | $1.16B | +4% | -2% | 3% | 16.6× | -16.0% | +6.5% |
| Ain 9627.T | Japan | $1.25B | +2% | +42% | 4% | 13.8× | -6.5% | +16.9% |
| Create SD 3148.T | Japan | $1.32B | +3% | +9% | 5% | n/a | -11.5% | +8.0% |
| Landfar Bio-medicine 000504.SZ | China | $351M | -22% | +497% | -2% | n/a | n/a | n/a |
| LBX Pharmacy Chain Joint Stock 603883.SS | China | $1.71B | +13% | +3% | 5% | 16.1× | -10.7% | +9.7% |
| Shanghai No. 1 Pharmacy 600833.SS | China | $299M | -22% | +1% | -1% | n/a | 19.5% | +6.1% |
| JZJ Chain Drugstore Corporation 605266.SS | China | $293M | -35% | -5% | 0% | 6.2× | -9.9% | +14.8% |